No annual revenue total was found in Akari Therapeutics Plc's SEC filings.
Akari Therapeutics Plc (AKTX) files with the SEC under industry code 2834, Pharmaceutical Preparations.
Revenue
—
Net income (TTM)
$-30.96M
-152.4% vs year-ago TTM
Operating cash flow (TTM)
$-10.76M
-19.3% vs year-ago TTM
Free cash flow
$-12.92M
+43.3% vs prior year
EPS (TTM)
$-0.00
-10.2% vs year-ago TTM
Dividend per share
None
Shares outstanding
91.57B
+58.5% vs prior year
Net cash
—
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- AKTX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- United Kingdom
- Headquarters
- Tampa, FL
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1541157
- Former names
- Celsus Therapeutics Plc. (until Sep 15, 2015); Morria Biopharmaceuticals PLC (until Jun 20, 2013)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Operating income | -$17.3M | -$21.6M | -$16.8M | -$23.1M | -$17.2M |
| Net income | -$17.3M | -$19.8M | -$10.0M | -$17.7M | -$17.4M |
| Diluted EPS | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating cash flow | -$10.6M | -$12.6M | -$16.4M | -$21.5M | -$18.8M |
| Total assets | $47.9M | $50.6M | $4.4M | $13.8M | $11.6M |
| Total liabilities | $19.6M | $28.3M | $4.6M | $12.0M | $6.1M |
| Stockholders' equity | $28.3M | $22.2M | -$229,000 | $1.8M | $5.6M |
| Cash and investments | $0 | $0 | $3.8M | $13.2M | $9.4M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Shareholder vote results
|
Oct 30, 2026 | Oct 28, 2026 |
| 8-K |
Current report
Officer or director change
|
Oct 1, 2026 | Sep 29, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 13, 2026 | Aug 13, 2026 |
| 10-Q | Quarterly report | Aug 13, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jul 2, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Material agreement
|
Jun 26, 2026 | Jun 23, 2026 |
All 743 Akari Therapeutics Plc SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.